Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dibutyl Phthalate SCHEMBL18094424 | 0.90 | TSHR (0.69) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 | |
| Diethyl Phthalate SCHEMBL321970 | 0.87 | TSHR (0.66) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 | |
| Citric Acid SCHEMBL25266373 | 0.83 | ALDH1A1 (0.52) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL317666 | 0.83 | ALDH1A1 (0.52) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 | |
| Dibutyl Sebacate SCHEMBL28232117 | 0.82 | TSHR (0.52) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 | |
| Dibutyl Phthalate SCHEMBL5916298 | 0.81 | TSHR (0.64) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 | |
| Tributyl Citrate SCHEMBL16348681 | 0.81 | TSHR (0.68) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 | |
| Glycolic Acid SCHEMBL28525255 | 0.81 | TSHR (0.76) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 | |
| Ammonia Solution, Strong SCHEMBL6657318 | 0.80 | ALDH1A1 (0.48) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL25201606 | 0.79 | ALDH1A1 (0.47) | TSHRTDP1L3MBTL1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3644995-A1 | DEUTERATED DOMPERIDONE COMPOSITIONS, METHODS, AND PREPARATION | CinDome Pharma, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019006078-A1 | DEUTERATED DOMPERIDONE COMPOSITIONS, METHODS, AND PREPARATION | CINRX PHARMA, LLC (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2018165404-A1 | PHARMACEUTICAL FORMUALTIONS OF PHLOROGLUCINOL AND TRIMETHYLPHLOROGLUCINOL | CINRX PHARMA, LLC (US) | 2018-09-13 | — | — | WO | disclosed |
| US-20110189286-A1 | Pulsatile Release of Valsartan | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| EP-2285358-A1 | PULSATILE RELEASE OF VALSARTAN | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009148990-A1 | PULSATILE RELEASE OF VALSARTAN | NOVARTIS AG (CH) | 2009-12-10 | — | — | WO | disclosed |
| EP-1976491-A2 | DRUG DELIVERY SYSTEMS COMPRISING WEAKLY BASIC SELECTIVE SEROTONIN 5-HT3 BLOCKING AGENT AND ORGANIC ACIDS | Eurand, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007090082-A2 | DRUG DELIVERY SYSTEMS COMPRISING WEAKLY BASIC SELECTIVE SEROTONIN 5-HT3 BLOCKING AGENT AND ORGANIC ACIDS | EURAND, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1670447-A1 | MODAFINIL MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS | CEPHALON, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005027890-A1 | MODAFINIL MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS | CEPHALON, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2003051343-A1 | PULSATILE RELEASE HISTAMINE H2 ANTAGONIST DOSAGE FORMS | EURAND, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2001080824-A2 | DUAL MECHANISM TIMED RELEASE DOSAGE FORMS FOR LOW DOSE DRUGS | EURAND AMERICA, INC. (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001058433-A1 | TIMED PULSATILE DRUG DELIVERY SYSTEMS | EURAND PHARMACEUTICALS LTD. (IE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189286-A1 | Pulsatile Release of Valsartan | TMPRSS15, AVPR2, VIPR1 | TSHR 1939/4885TDP1 3988/4885L3MBTL1 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.